Rank,NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age
1,NCT04785898,Diagnostic Performance of the ID Now™ COVID-19 Screening Test Versus Simplexa™ COVID-19 Direct Assay,COVID-IDNow,"Active, not recruiting",No Results Available,Covid19,Diagnostic Test: ID Now™ COVID-19 Screening Test,Evaluate the diagnostic performance of the ID Now ™ COVID-19 test carried out by nurses in an emergency department in comparison with the reference PCR test: Simplexa ™ COVID-19 Direct,Groupe Hospitalier Paris Saint Joseph,All,"18 Years and older   (Adult, Older Adult)"
2,NCT04595136,Study to Evaluate the Efficacy of COVID19-0001-USR in Patients With Mild/or Moderate COVID-19 Infection in Outpatient,COVID-19,Not yet recruiting,No Results Available,SARS-CoV-2 Infection,Drug: Drug COVID19-0001-USR|Drug: normal saline,Change on viral load results from baseline after using COVID19-0001-USR via nebulization,United Medical Specialties,All,"18 Years and older   (Adult, Older Adult)"
3,NCT04395482,Lung CT Scan Analysis of SARS-CoV2 Induced Lung Injury,TAC-COVID19,Recruiting,No Results Available,covid19,Other: Lung CT scan analysis in COVID-19 patients,A qualitative analysis of parenchymal lung damage induced by COVID-19|A quantitative analysis of parenchymal lung damage induced by COVID-19|The potential impact of parenchymal morphological CT scans in patients with severe moderate respiratory failure.|Automated segmentation of lung scans of patients with COVID-19 and ARDS.|Knowledge of chest CT features in COVID-19 patients and their detail through the use of machine learning and other quantitative techniques.|The ability within which the analysis of artificial intelligence that uses deep learning models can be used to predict clinical outcomes,University of Milano Bicocca,All,"18 Years and older   (Adult, Older Adult)"
4,NCT04416061,The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic,COVID-19,"Active, not recruiting",No Results Available,COVID,Diagnostic Test: COVID 19 Diagnostic Test,Proportion of asymptomatic subjects|Proportion of subjects with recent contact history|Proportion of subjects with recent travel history,Hong Kong Sanatorium & Hospital,All,"Child, Adult, Older Adult"
5,NCT04395924,Maternal-foetal Transmission of SARS-Cov-2,TMF-COVID-19,Recruiting,No Results Available,Maternal Fetal Infection Transmission|COVID-19|SARS-CoV 2,"Diagnostic Test: Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta",COVID-19 by positive PCR in cord blood and / or positive serologies|COVID-19 by positive PCR in amniotic fluid and placenta|New born infected by COVID-19,Centre Hospitalier Régional d'Orléans|Centre de Biophysique Moléculaire - Pr Chantal Pichon|Professeur TOUMI Hechmi,Female,18 Years to 48 Years   (Adult)
6,NCT04516954,Convalescent Plasma for COVID-19 Patients,CPCP,Enrolling by invitation,No Results Available,COVID 19,Biological: Convalescent COVID 19 Plasma,Evaluate the safety|Change in requirement for mechanical ventilatory support,"Vinmec Research Institute of Stem Cell and Gene Technology|National Institute of Hygiene and Epidemiology, Vietnam|National Hospital for Tropical Diseases, Hanoi, Vietnam|National Institute of Hematology and Blood Transfusion, Vietnam",All,"18 Years to 75 Years   (Adult, Older Adult)"
7,NCT04476940,COVID-19 Breastfeeding Guideline for African-Americans,COVID-BF,Not yet recruiting,No Results Available,Covid19|Exclusive Breastfeeding,Behavioral: COVID-19 Breastfeeding Support,COVID-19 breastfeeding guidance adherence at birth.|COVID-19 breastfeeding guidance adherence at 1-month postpartum.|COVID-19 breastfeeding guidance adherence at 3-months postpartum.|Exclusive breastfeeding at birth.|Exclusive breastfeeding at 1-month.|Exclusive breastfeeding at 3-months.|COVID_Status|COVID-19 Immunoglobulin G|COVID-19 Immunoglobulin M,Meharry Medical College,Female,18 Years to 45 Years   (Adult)
8,NCT04634214,The Severity of COVID 19 in Diabetes and Non-diabetes Patients,COVID19,Not yet recruiting,No Results Available,Covid19|Type2 Diabetes,,"Severity of COVID 19 among people with and without diabetes|Number of patients who were in ICU|Number of patients who had tracheal intubation|Number of patients who had respiratory complication|Number of death|Correlation of BMI with complications, tracheal intubation and mortality|Length of hospital stay",India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals,All,"18 Years to 99 Years   (Adult, Older Adult)"
9,NCT04602884,Early Detection of COVID-19 Using Breath Analysis,COVID-19,Suspended,No Results Available,Covid19,Diagnostic Test: Breath biopsy sampling using the ReCIVA Breath Sampler,Correlation between Volatile Organic Compounds pattern and COVID-19 detection status.|Correlation between Volatile Organic Compounds pattern and time from COVID-19 detection.|Correlation between the set of Volatile Organic Compounds found in breath biopsy and disease intensity.,Scentech Medical Technologies Ltd,All,18 Years to 55 Years   (Adult)
10,NCT04384588,COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID),FALP-COVID,Recruiting,No Results Available,COVID-19 Infection|Cancer Patients|General Population,Biological: Convalescent Plasma from COVID-19 donors,"in-hospital mortality secondary to COVID-19 among patients treated with convalescent plasma|safety of the use of convalescent plasma drom COVID 19 donors|Mortality at 30 days, 90 days, 6 months and 1 year|in-hospital Mortality COVID-19 related compared with non-treated population according to Chilean official reports|Number of days of hospitalization in high complexity facilities after convalescent plasma use|Number of days of hospitalization in intensive care unit after convalescent plasma use|Number of days of mechanical ventilatory support in patients after convalescent plasma use|Total number of days of mechanical ventilatory support|Total number of hospitalization days in patients treated with convalescent plasma|Number of hospitalization days in patients after treatment with convalescent plasma|Viral load measuring|Immunological response in treated patients (COVID19-Immunoglobulin M and Immunoglobulin G, neutralizing antibodies)|Negativization of COVID 19 load since convalescent plasma use|Negativization of COVID 19 load since hospitalization|Negativization of COVID 19 load since first reported symptoms COVID-19 related|Donor Interferon Gamma profile characterization|Donor Granulocyte Macrophage Colony Stimulating Factor characterization|Donor Tumor Necrosis Factor Alfa characterization|Donor Interleukin -1 beta characterization|Donor Interleukin-2 characterization|Donor Interleukin-4 characterization|Donor Interleukin-6 characterization|Donor Interleukin-8 characterization|Donor Interleukin-10 characterization|Receptor Interferon Gamma profile characterization|Receptor Granulocyte Macrophage Colony Stimulating Factor characterization|receptor Tumor Necrosis Factor Alfa characterization|receptor Interleukin -1 beta characterization|Receptor Interleukin-2 characterization|Receptor Interleukin-4 characterization|Receptor Interleukin-6 characterization|Receptor Interleukin-8 characterization|Receptor Interleukin-10 characterization",Fundacion Arturo Lopez Perez|Confederación de la Producción y del Comercio (CPC)|Bolsa de Santiago,All,"15 Years and older   (Child, Adult, Older Adult)"
11,NCT04355897,CoVID-19 Plasma in Treatment of COVID-19 Patients,,Recruiting,No Results Available,COVID 19,Biological: Convalescent COVID 19 Plasma,Reduce mortality|Reduce requirement for mechanical ventilation.|Reduce the duration of mechanical ventilation.|Review of treatment related adverse events.,The Christ Hospital,All,"18 Years to 80 Years   (Adult, Older Adult)"
12,NCT04412265,Frailty in Elderly Patients With COVID-19,FRA-COVID,Recruiting,No Results Available,Covid19,Other: Relation between frailty and clinical outcomes in elderly patients with COVID-19.,"Development of a tool to measure frailty|A ""proxy"" variable of the fragility index can be built on the basis of regional administrative databases only.|Give elements to focus the screening policies for COVID19.|Give the prevention of contagion at the elderly population level.",University of Milano Bicocca,All,"18 Years and older   (Adult, Older Adult)"
13,NCT04659759,"COVID-19 Pregnancy Related Immunological, Clinical and Epidemiological Factors and Perinatal Outcomes",COVID-PRICE,Recruiting,No Results Available,Covid19,Other: COVID-19 exposure|Biological: COVID-19 vaccine,Maternal COVID-19 serology (IgG and IgM)|Maternal/neonatal IgG and IgM concordance|Maternal COVID serology time/profile following vaccination|Breastmilk Serology|Cytokine|Neonatal cytokine|COVID disease vs vaccination immune response|COVID vaccine in pregnant vs nonpregnant,Thomas Jefferson University|Nemours,Female,"Child, Adult, Older Adult"
14,NCT04427332,Smell and Taste Disorders in COVID-19 Patients,COVID-19 ORL,Completed,No Results Available,covid19,Other: Investigation of smell and taste disorders,Identification of demographic and clinical factors in covid19 patients.|Description of the disturbances of smell and taste|Description of factors that influence smell and taste,University of Milano Bicocca,All,"18 Years and older   (Adult, Older Adult)"
15,NCT04842708,Evaluation of Anti-COVID 19 Pfizer Vaccination Effect on COVID 19 Detection Using Breath Analysis,COVID-19,Recruiting,No Results Available,Covid19,Diagnostic Test: vaccination against COVID19,Association between breath VOCs and IgG in blood following second vaccination dose.|Association between VOCs profile and participants' clinical or demographic characteristics,Scentech Medical Technologies Ltd,All,"18 Years to 75 Years   (Adult, Older Adult)"
16,NCT04367805,COVID-19 Infection in Patients With Hepatocellular Carcinoma,COVID19-CHIEF,Recruiting,No Results Available,Hepatocellular Carcinoma|COVID-19,Diagnostic Test: nasopharyngeal Covid 19 RT-PCR,Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France,"Centre Hospitalier Universitaire, Amiens|Centre Hospitalier-Universitaire Bondy|University Hospital, Bordeaux|Centre Hospitalier-Universitaire CLICHY|Centre Hospitalier Général CORBEIL-ESSONNE|CHU CRETEIL|University Hospital, Grenoble|University Hospital, Lille|CHU LYON|Poitiers University Hospital|Rennes University Hospital|University Hospital, Rouen|University Hospital, Toulouse|CHU VILLEJUIF|Central Hospital, Nancy, France|Centre Hospitalier Universitaire de Nice|University Hospital, Montpellier",All,"18 Years and older   (Adult, Older Adult)"
17,NCT04609969,Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test,COVID-VIRO,Completed,No Results Available,Covid19|SARS-CoV-2 Infection,Diagnostic Test: RT-qPCR test|Diagnostic Test: COVID-VIRO® test,Evaluation of COVID VIRO® diagnostic specificity|Evaluation of COVID VIRO® diagnostic sensitivity|Evaluation of COVID VIRO® diagnostic sensitivity for RT-qPCR Cycle threshold value < or > 28,Centre Hospitalier Régional d'Orléans,All,"18 Years and older   (Adult, Older Adult)"
18,NCT04817553,Impact of COVID-19 on the Clinical Outcomes and Management of IgG4 Related Disease Patients,IgG4-COVID,Recruiting,No Results Available,IgG4 Related Disease|Covid19,Other: exposure to COVID19,Incidence of COVID-19 in IgG4 patients with pancreatobiliary involvement|Incidence of severe COVID-19 in IgG4 patients with pancreatobiliary involvement|Medications for the underlying IgG4 disease used when patient was diagnosed to have COVID-19|Risk factors associated with COVID-19 infection in IgG4 patients with pancreatobiliary involvement|Incidence of postponement or discontinuation of indicated medical treatment for the underlying IgG4 disease during COVID-19 outbreak,Chinese University of Hong Kong,All,"18 Years and older   (Adult, Older Adult)"
19,NCT04632355,Musculoskeletal Pain in Patients With Covid-19 Who Have Hospital Care,Covid19-Pain,Not yet recruiting,No Results Available,Covid19,Other: Interview,Self-reported Version of the Leeds Assessment of Neuropathic Symptoms and Signs|PainDETEC|EuroQol-5D|The Hospital Anxiety and Depression Scale,Fondazione Don Carlo Gnocchi Onlus,All,"18 Years and older   (Adult, Older Adult)"
20,NCT04407585,Testing the Accuracy of a Digital Test to Diagnose Covid-19,,Recruiting,No Results Available,Covid-19,Diagnostic Test: Covid-19 swab PCR test,SARS-CoV-2 infection,"King's College London|Zoe Global Limited|Department of Health, United Kingdom",All,"18 Years and older   (Adult, Older Adult)"
21,NCT04657510,Femoral frACturEs and COVID-19.,FACE COVID-19,Recruiting,No Results Available,Covid19|Femur Fracture|Fragility Fracture,Other: COVID-19,Survival at discharge day (comparison between the two groups)|Length of stay (comparison between the two groups)|Readmission rate (comparison between the two groups)|Complications rate (comparison between the two groups)|Survival at 30 days after discharge (comparison between the two groups)|Routine lab exams values (comparison between the two groups),Istituto Ortopedico Galeazzi,All,"45 Years and older   (Adult, Older Adult)"
22,NCT04473170,Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19,SENTAD-COVID,Completed,No Results Available,Coronavirus Disease 2019 (COVID-19),Biological: Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)|Drug: COVID-19 standard care,Adverse reactions incidence.|Rate of mortality within 28-days.|Time to clinical improvement on a seven-category ordinal scale.|Assessment of the immune response profile.|Assessment of acute-phase serum markers.,Abu Dhabi Stem Cells Center,All,"18 Years and older   (Adult, Older Adult)"
23,NCT04497298,Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine,COVID-19-101,"Active, not recruiting",No Results Available,COVID-19,Biological: Two COVID-19 vaccine candidate (TMV-083) administrations - Low dose|Biological: Two COVID-19 vaccine candidate (TMV-083) administrations - High dose|Biological: One COVID-19 vaccine candidate (TMV-083) administration - High dose|Other: Placebo,"To assess the safety and tolerability of the COVID-19 vaccine following one or two consecutive intramuscular injections in healthy volunteers|To assess induction of SARS-CoV-2 spike protein-binding antibodies upon one or two administrations of the COVID-19 vaccine by means of ELISA up to study day 56|To assess induction of SARS-CoV-2 neutralizing antibodies upon one or two administrations of the COVID-19 vaccine by means of serum neutralization assay up to study day 91|To assess SARS-CoV-2 spike protein-specific, cell-mediated immune responses up to study day 91, induced by one or two doses of vaccine, by means of intracellular staining and flow cytometry.|To assess potential measles virus shedding by means of RT-qPCR of saliva, nasal swab, urine, or blood samples in sentinel groups on day 0 and up to day 42",Institut Pasteur|Themis Bioscience GmbH|Coalition for Epidemic Preparedness Innovations,All,18 Years to 55 Years   (Adult)
24,NCT04549831,Genetic Bases of COVID-19 Clinical Variability,GEN-COVID,Recruiting,No Results Available,COVID-19,Genetic: Massive parallel sequencing of host genome,To identify the genetic determinants of COVID-19 severity|To identify the genetic determinants of COVID-19 clinical trajectories.,"University of Siena|Policlinico San Matteo Pavia Fondazione IRCCS|Ospedale San Donato, Arezzo|Ospedale della Misericordia|Azienda Ospedaliera Ospedale Maggiore di Crema|University of Modena and Reggio Emilia|ASST Fatebenefratelli Sacco|Azienda Ospedaliera di Perugia|Ospedale dell'Angelo, Venezia-Mestre|Azienda Ulss 2 Marca Trevigiana|Cardarelli Hospital|Azienda Ospedaliera dei Colli|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|Istituto Giannina Gaslini|Istituti Ospitalieri di Cremona|IRCSS Lazzaro Spallanzani, Roma|ASST Santi Paolo e Carlo|ASST Valtellina e Alto Lario|Azienda USL Toscana Sud Est|ULSS1 Dolomiti, Belluno|ASST Spedali Civili, Brescia|IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo|Fondazione Policlinico Universitario Agostino Gemelli IRCCS|Ospedale Luigi Curto, Polla|Istituto Auxologico Italiano|CEINGE Biotecnologie Avanzate, Napoli",All,"18 Years and older   (Adult, Older Adult)"
25,NCT04706390,Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination,COVID19vac-1,Recruiting,No Results Available,Covid19,Biological: covid-19 vaccine,immune responses|Duration and breadth of B- and T cell responses|Immune responses in healthy people and patient groups at risk,University of Bergen|Haukeland University Hospital,All,"20 Years to 100 Years   (Adult, Older Adult)"
26,NCT04632719,The MentalPlus® for Assessment and Rehabilitation of Cognitive Function After Remission of the Symptoms of COVID-19,MP-COVID,Recruiting,No Results Available,"Cognitive Impairment|Covid19|Cognitive Dysfunction|Depression, Anxiety|Quality of Life",Device: The use of the MentalPlus® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19,Assessment of cognitive functions after COVID-19|Rehabilitation of cognitive functions after COVID-19,University of Sao Paulo,All,"8 Years to 88 Years   (Child, Adult, Older Adult)"
27,NCT04427345,Predictive Factors COVID-19 Patients,MI-COVID,Recruiting,No Results Available,covid19,Other: Predictive factors for clinical response in patients with COVID-19.,"Identify risk factors for intra-hospital mortality.|Identify risk factors to build a prognostic score.|Predictive factors for the hospitalization duration.|Predictive factors for clinical status patients based on ""Ordinal Scale for Clinical Improvement""|Describe the anti-viral therapies used commonly in this emergency in terms of efficacy|Describe the anti-viral therapies used commonly used in this emergency in terms of safety|Monitor the clinical course of the disease in discharged patients.",University of Milano Bicocca,All,"18 Years and older   (Adult, Older Adult)"
28,NCT04424004,MURDOCK Cabarrus County COVID-19 Prevalence and Immunity (C3PI) Study,C3PI,"Active, not recruiting",No Results Available,COVID 19,Other: COVID-19 PCR and serology testing,"Estimate the prevalence of COVID-19 infection based on responses to questionnaire items on symptoms and practices using a biweekly electronic survey.|Assess perceptions, concerns, and practices related to the COVID-19 pandemic and mitigation strategies|Estimate of the prevalence of active infection in Cabarrus County.|Estimate of the prevalence of exposure and potential immunity to COVID-19.",Duke University|North Carolina Department of Health and Human Services,All,"18 Years and older   (Adult, Older Adult)"
29,NCT04407494,Diagnostic Value of Patient - Reported and Clinically Verified Olfactory Disorders (COVID-19),COVID-OLFA,Completed,No Results Available,COVID-19,"Biological: Reporting of anosmia, ageusia and other clinical symptoms",Diagnostic values of anosmia and ageusia for COVID-19|Diagnostic values of CODA,"University Hospital, Montpellier",All,"18 Years and older   (Adult, Older Adult)"
30,NCT04360811,"Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic",COroFet,Recruiting,No Results Available,Pregnancy,Diagnostic Test: COVID 19 diagnostic test by PCR,number of positive COVID-19 women,"University Hospital, Toulouse",Female,"18 Years and older   (Adult, Older Adult)"
31,NCT04403672,Performance Evaluation of RealDetect™ COVID-19 RT-PCR Kit for the Detection of SARS-CoV-2 Virus,,Recruiting,No Results Available,High Sensitivity and Specificity (With 95% Confidence Interval) of RealDetect™ COVID-19 RT-PCR Kit,Device: performance evaluation study of RealDetect RT-PCR Kit for COVID-19 detection,Performance evaluation of RealDetect™ COVID-19 RT-PCR kit|Reduce the price of RT-PCR based COVID-19 diagnostic test kits.,Bangladesh Medical Research Council (BMRC),All,"5 Years to 65 Years   (Child, Adult, Older Adult)"
32,NCT04363099,Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.,COVID AMBU 60,Recruiting,No Results Available,Covid-19,Other: observational,clinical description of covid 19 ambulatory cases.|Biological and radiological description of ambulatory cases|Prevalence of positive cases (PCR and/or serological positive),Maison de Sante Pluridisciplinaire de Creil,All,"up to 99 Years   (Child, Adult, Older Adult)"
33,NCT04377425,COVID-19 Prevalence and Cognitive Deficits in Neurological Patients,Neuro-Covid,Withdrawn,No Results Available,"Neurological Diseases or Conditions|Stroke, Acute|Seizure Disorder",Diagnostic Test: COVID-19 swap test PCR,Prevalence of COVID-19 infection in consecutive patients with neurological symptoms|Three months cognitive function of COVID-19 positive patients|Clinical presentation of neurological symptoms in COVID-19 positive patients|Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients|Anosmia in COVID-19 positive patients|Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection|Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients,Aarhus University Hospital,All,"18 Years and older   (Adult, Older Adult)"
34,NCT04602871,Early Detection of COVID-19 Using Breath Analysis - Feasibility Study,COVID-19,Completed,No Results Available,Covid19,Diagnostic Test: Breath Biopsy,Correlation between Volatile Organic Compounds pattern in-breath biopsy and COVID-19 detection.|Correlation between Volatile Organic Compounds pattern and the course of the disease,Scentech Medical Technologies Ltd,All,"18 Years to 75 Years   (Adult, Older Adult)"
35,NCT04691895,Gastrointestinal Symptoms in COVID-19,,"Active, not recruiting",No Results Available,COVID19 Disease,Other: SARS-CoV2 infection,Prevalence of gastrointestinal symptoms in patients admitted to hospital for COVID19 disease as assessed by GSRS questionnaire|Prognosis of gastrointestinal symptoms in patients admitted to hospital for COVID19 disease|Long term consequences of COVID-19 on gastrointestinal symptoms on the development of post-infection (PI) irritable bowel syndrome (IBS).|long term consequences of COVID-19 on gastrointestinal symptoms on the development of post-infection (PI) dyspepsia.|Identification of risk factors for post-infection gastrointestinal symptom development.,University of Bologna,All,"18 Years to 85 Years   (Adult, Older Adult)"
36,NCT04645498,COVID-19 and Hereditary Metabolic Diseases,COVID19-MHM,Not yet recruiting,No Results Available,"Covid19|Metabolism, Inborn Errors",,Frequency of MHM imbalance triggered by COVID-19|Number of COVID-19 patients in Gaucher's disease|Number of COVID-19 patients in Urea Cycle Disorder|Severity of COVID-19 infection,"University Hospital, Lille",All,"Child, Adult, Older Adult"
37,NCT04747821,An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine,Projeto S,"Active, not recruiting",No Results Available,Covid19,Biological: Adsorbed COVID-19 (Inactivated) Vaccine,Incidence of COVID-19 cases after two-doses immunization schedule in clusters in the first quarter of study|Incidence of COVID-19 cases after two-doses immunization schedule in clusters up to one year of study|Incidence of COVID-19 cases after two-doses immunization schedule in clusters according to immunization status|Incidence of COVID-19 cases after two-doses immunization schedule in clusters according to pre-existing SARS-CoV-2 antibodies|Incidence of COVID-19 cases after two-doses immunization schedule in clusters according to immunization coverage|Incidence of hospitalization and death due to COVID-19 after two-doses immunization schedule in clusters|Change in average number of reported COVID-19 cases in the study area in comparison to other neighboring cities|Medically-attended adverse reactions to the study vaccine|Frequency of severe COVID-19 cases|Frequency of adverse events of special interest after immunization|Acceptability of the study vaccine|Adherence to vaccination schedule,Butantan Institute,All,"18 Years and older   (Adult, Older Adult)"
38,NCT04372004,Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19),CATCH COVID-19,Recruiting,No Results Available,COVID-19,Diagnostic Test: diagnostic tests for COVID-19 infection,detection of viral infection using serology and viral-RNA detection kits|Temporal trend of antibodies in blood,Texas Cardiac Arrhythmia Research Foundation,All,"18 Years to 85 Years   (Adult, Older Adult)"
39,NCT04377685,Prediction of Clinical Course in COVID19 Patients,COVID-CTPRED,Recruiting,No Results Available,COVID 19,Other: CT-Scan,diagnostic of COVID disease composite,"Centre Hospitalier Universitaire de Saint Etienne|Institut National des Sciences Appliquées (INSA)|Institut National de la Santé Et de la Recherche Médicale, France|Centre National pour le Recherche Scientifique (CNRS)|Université de Lyon|Université Jean Monnet",All,"18 Years and older   (Adult, Older Adult)"
40,NCT04717011,Case Series Study to Detect SARS-CoV-2 in Semen of COVID-19 Patients,COVID-19CAST,Recruiting,No Results Available,SARS-CoV-2,Diagnostic Test: PCR test,SARS-CoV-2 semen result,Igenomix,Male,"18 Years to 65 Years   (Adult, Older Adult)"
41,NCT04412486,COVID-19 Convalescent Plasma (CCP) Transfusion,,Recruiting,No Results Available,COVID-19,Biological: COVID Convalescent Plasma,Change in PaO2/FiO2 after CCP transfusion.|Change in pulse oximetry status after CCP transfusion.|Change in aO2 after CCP transfusion.|Change in respiratory rate after CCP transfusion.|Change in intubation status after CCP transfusion.|Change in Sequential Organ Failure Assessment (SOFA).|Change in 8-point ordinal clinical deterioration scale.|Length of ICU/hospital stay.|Development of plasma transfusion reactions.|Development of immune complex disorders.|Change in anti CoV-2 IgM and IgG levels.,"Gailen D. Marshall Jr., MD PhD|University of Mississippi Medical Center",All,"18 Years and older   (Adult, Older Adult)"
42,NCT04581135,Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19,,Recruiting,No Results Available,COVID-19,Other: COVID-19,Pulmonary follow-up sequelae in patients after COVID-19|Evaluation of risk factors for adverse Outcome after COVID-19|Compare the functional Pulmonary outcome of COVID-19 disease|Compare the radiological Pulmonary outcome of COVID-19 disease|Quality of Life after COVID-19|Physical performance after COVID-19 using Clinical Frailty Scale|Physical performance after COVID-19 using frailty assessment tests|Microbiota and COVID-19,"University Hospital Inselspital, Berne",All,"18 Years and older   (Adult, Older Adult)"
43,NCT04387968,"Epidemiological Study of the Covid-19 Presto Test - The ""COVIDOR"" Study",COVIDOR,Recruiting,No Results Available,Coronavirus Infection,Diagnostic Test: Covid-19 presto test,"Study the prevalence of Covid-19 infection, coronavirus (SARS coronavirus-2) in territorial agents in the 3 structures : CCTVL, Loire Valley Region Centre, Orleans Metropolitan city|Determine if there is a relationship between the profession carried out by the agents of the territorial community of Orleans metropolitan city, the Loire Valley Region, the CCTVL and contamination by covid-19","Raphael Serreau|François Rabelais University|Assistance Publique - Hôpitaux de Paris|University Hospital, Paris|Orléans Métropole Service de Médecine Préventive",All,"18 Years to 65 Years   (Adult, Older Adult)"
44,NCT04845048,Active Pharmacovigilance Study of Adsorbed COVID-19 (Inactivated) Vaccine,,Not yet recruiting,No Results Available,Covid19,Biological: Adsorbed COVID-19 (Inactivated) Vaccine,Incidence of adverse events after receiving the Adsorbed COVID-19 (inactivated) Vaccine|Reactogenicity of Adsorbed COVID-19 (inactivated) Vaccine|Safety of Adsorbed COVID-19 (inactivated) Vaccine|safety of Adsorbed COVID-19 (inactivated) Vaccine,Butantan Institute,All,"18 Years and older   (Adult, Older Adult)"
45,NCT04490837,Rapid Diagnostic Test for COVID-19 Based on Antibody Detection (YCOVID),YCOVID,"Active, not recruiting",No Results Available,Covid-19,Diagnostic Test: ELISA and Rapid test to detect antibodies against COVID-19,IgG anti-COVID-19|IgM anti-COVID-19|IgA anti-COVID-19|Time of onset symptoms|COVID-19 PCR results|Radiological studies,Corporacion Parc Tauli,All,"18 Years and older   (Adult, Older Adult)"
46,NCT04834908,Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection,PROTECT,Not yet recruiting,No Results Available,SARS-CoV-2 Infection,Biological: Equine COVID-19 Antiserum|Drug: Standard of care,Phase 1 Unexpected serious adverse events|Phase 2 Patients turning COVID-19 negative (RT-PCR negative)|Phase 2 Patients turning COVID-19 negative (RT-PCR Negative)|Phase 1 Patients turning COVID-19 negative (RT-PCR Negative)|Phase 1 Exploratory outcome|Phase 1-Exploratory outcome|Phase 1- Exploratory outcome|Phase 2 Unexpected serious adverse events|Phase 2 Change in WHO clinical progression scale,Bharat Serums and Vaccines Limited,All,"18 Years to 65 Years   (Adult, Older Adult)"
47,NCT04730401,Convalescent Plasma in the Treatment of Covid-19,CP_COVID-19,Recruiting,No Results Available,Covid19,Biological: Convalescent plasma from COVID-19 donors|Biological: Placebo,Safety (SAE)|Rate of intubation|Number of participants initiating systemic corticosteroids|Hospital stay|Mortality|ICU stay|Ventilator days|Severity of respiratory failure|Viral load|Antibody measurements|Thrombotic complication|The rate of participants presenting with coagulopathy disorders|Number of participants with laboratory change|Adverse effects|Convalescent plasma efficacy|Convalescent plasma high vs low titer efficacy|Convalescent plasma efficacy according to donor status,Helsinki University Central Hospital|Finnish Red Cross,All,"18 Years and older   (Adult, Older Adult)"
48,NCT04799444,LATE-COVID/LATE-COVID-Kids - Observational Study in Children and Adults,LATE-COVID,Recruiting,No Results Available,Covid19,,Number of participants with severe post-COVID-19 complications|Factors related to the severity of post-COVID-19 complications,Polish Mother Memorial Hospital Research Institute,All,"Child, Adult, Older Adult"
49,NCT04425707,Ivermectin In Treatment of COVID 19 Patients,,Recruiting,No Results Available,Covid19,Drug: Ivermectin,to evaluate the role of Ivermectin as a line of treatment for COVID 19|To asses the rate of viral clearance in comparison to other treatment protocols.,"Ministry of Health and Population, Egypt",All,"18 Years and older   (Adult, Older Adult)"
50,NCT04356560,COVID-19 Surveillance of Patients and Healthcare Workers in a Hospital Department,,Enrolling by invitation,No Results Available,COVID-19,"Diagnostic Test: COVID-19 test, polymerase chain reaction for SARS-CoV-2",Incidence of healthcare workers with SARS-CoV-2|Incidence of ENT patients with SARS-CoV-2|Development of SARS-CoV-2 antibodies among healthcare workers|Sensitivity and specificity of a COVID-19 screening symptom questionnaire among healthcare workers|SARS CoV-2 and bacterial super infections in upper respiratory airways,"Rigshospitalet, Denmark",All,"Child, Adult, Older Adult"
51,NCT04598620,Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate,VTE-COVID-19,Recruiting,No Results Available,Covid19|Corona Virus Infection,,Prediction of admission to ICU in hospitalized COVID-19 patients|Pathophysiology in COVID-19 patients,Inger Lise Gade|Aarhus University Hospital Skejby|Aalborg University Hospital,All,"18 Years and older   (Adult, Older Adult)"
52,NCT04386109,Neonatal Complications of Coronavirus Disease (COVID-19),,Recruiting,No Results Available,Neonatal COVID-19 Disease,Other: No intervention - exposure is to COVID-19,Incidence of neonatal COVID-19|Incidence of vertically transmitted COVID-19|Presentation and natural history of neonatal COVID-19|Presentation of neonates with COVID-19 positive mothers|Outcomes for neonates with COVID-19|Clinical treatment of neonatal COVID-19|Neonatal secondary impacts of maternal COVID-19,"University of Oxford|Imperial College London|University of Leicester|University of Nottingham|University of Glasgow|University Hospital of Wales|Public Health England|St George's, University of London",All,up to 29 Days   (Child)
53,NCT04575168,Clinical Study Spartan COVID-19 V2 System,,Recruiting,No Results Available,Covid19,Diagnostic Test: Spartan COVID-19 Test,Percent Agreement between SOC test and Spartan COVID-19 test,Spartan Bioscience Inc.|Beaufort,All,"18 Years and older   (Adult, Older Adult)"
54,NCT04437940,Evaluation of Vaginal Fluid for Covid-19 Positivity in Women With Positive Nasofarengeal Covid-19 Test,,Completed,No Results Available,COVID|Sars-CoV2,Diagnostic Test: Vaginal fluid Covid-19 PCR test,Vaginal fluid Covid-19 PCR test result|becoming negative from positive,Acibadem University,Female,"18 Years to 70 Years   (Adult, Older Adult)"
55,NCT04508075,"Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine",COVID-19,"Active, not recruiting",No Results Available,SARS-CoV2 Infection,Biological: SARS-CoV-2 vaccine (inactivated)|Biological: Placebo,"Incidence of laboratory-confirmed COVID-19 after the second dose|Incidence of suspected COVID-19 cases|Incidence of laboratory-confirmed cases (severe, critical and death)|Seroconversion rate anti-S antibody IgG titer (ELISA)|Seropositive rate of neutralizing antibodies","PT Bio Farma|Faculty of Medicine Universitas Padjadjaran|National Intitute of Health Research and Development, Ministry of Health Republic of Indonesia|Sinovac Life Sciences Co., Ltd.",All,18 Years to 59 Years   (Adult)
56,NCT04628208,Clinical Study Spartan COVID-19 V2 System (Canada Alternate),,Recruiting,No Results Available,Covid19,Diagnostic Test: Spartan COVID-19 v2 System,Percent Agreement between SOC test and Spartan COVID-19 test,Spartan Bioscience Inc.,All,"18 Years and older   (Adult, Older Adult)"
57,NCT04750330,Mitochondrial DNA and Nuclear SNPs to Predict Severity of COVID-19 Infection,mtDNA-COVID,Not yet recruiting,No Results Available,Covid19,,COVID-19 Severity|Overall survival of the hospitalized population,Maastricht University|Innovative Medicines Initiative,All,"18 Years and older   (Adult, Older Adult)"
58,NCT04602949,Detection of COVID-19 Using Breath Analysis - Validation Study,COVID-19,Recruiting,No Results Available,Covid19,Diagnostic Test: Breath Biopsy Analysis,"Presence of Volatile Organic Compounds indicating carriers of COVID-19.|Association of exhaled biomarkers with participants' characteristics (age, gender, symptoms-severity, etc.).|sensitivity level of biomarkers' algorithm.",Scentech Medical Technologies Ltd,All,"18 Years to 75 Years   (Adult, Older Adult)"
59,NCT04376398,Survey: COVID-19 Patients Managed in the Operating Theatre of Belgian Hospitals,COVID,Completed,No Results Available,COVID-19,,Global evaluation of the implication of the Belgian anesthesiologists during COVID-19 pandemic|If any compare our results with other countries,Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Society for Anesthesia and Resuscitation of Belgium,All,"up to 100 Years   (Child, Adult, Older Adult)"
60,NCT04563247,Seroprevalence of SARS-CoV-2 in Asymptomatic Frontline COVID-19 HCWs,,Completed,No Results Available,Covid19,Diagnostic Test: IgG SARS CoV 2 antibodies,SARS CoV 2 IgG antibodies,Lahore General Hospital,All,20 Years to 60 Years   (Adult)
61,NCT04379310,Evaluation of Clinical Parameters on Admission and Medications in Covid-19 Pneumonia (Corona Virus Disease 2019),Covid-19,Completed,No Results Available,Covid-19,Drug: ACE Inhibitors and Calcium Channel Blockers,extend of lung involvement|oxygen saturation on admission,Nisantasi University,All,"18 Years to 99 Years   (Adult, Older Adult)"
62,NCT04682132,Polk COVID-19 and Flu Response,PCFR,"Active, not recruiting",No Results Available,Covid19,"Diagnostic Test: COVID-19 antigen and antibody tests, and influenza rapid test",Prevalence of COVID-19 amongst county emergency personnel|Correlation of common COVID-19 symptoms with result of COVID-19 test|Co-existence of influenza and COVID-19 positive test results,Polk County Fire Rescue,All,"18 Years and older   (Adult, Older Adult)"
63,NCT04390074,COVID-19 in the Swedish ICU-cohort: Risk Factors of Critical Care Admission and Intensive Care Mortality,,Completed,No Results Available,COVID-19|Critical Illness,Other: COVID-19 and Intensive Care,Chronic medications as risk factor of intensive care for COVID-19|Comorbidities as risk factor of intensive care for COVID-19|Chronic medications as risk factor of death during intensive care for COVID-19|Comorbidities as risk factor of death during intensive care for COVID-19,"Uppsala University|Center for Clinical Research Dalarna, Sweden",All,"18 Years and older   (Adult, Older Adult)"
64,NCT04353206,Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure,,Recruiting,No Results Available,Covid-19|Sars-CoV2,Biological: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma,Proportion of subjects who consent to the study and receive at least one dose of convalescent plasma.|Overall survival of patients in the ICU receiving at least once dose of convalescent plasma for Covid-19-induced respiratory failure.,Noah Merin|Johns Hopkins University|Cedars-Sinai Medical Center,All,"18 Years and older   (Adult, Older Adult)"
65,NCT04460274,Forecast Number of Covid-19 Cases Worldwide,Covid19TmeSer,Completed,No Results Available,Covid-19,Other: Model Building|Other: Model validation,Number of Confirmed cases of Covid-19,Turkish Ministry of Health Izmir Teaching Hospital,All,"Child, Adult, Older Adult"
66,NCT04366271,Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19,MESCEL-COVID19,Recruiting,No Results Available,COVID,Biological: Mesenchymal cells|Drug: Standard of care,Mortality due to lung involvement due to SARS-CoV-2 virus infection at 28 days of treatment|Mortality due to lung involvement due to SARS-CoV-2 virus infection at 14 days of treatment|Mortality from any cause at 28 days|Days without mechanical respirator and without vasopressor treatment for 28 days|Patients alive without mechanical ventilation and without vasopressors on day 28|Patients alive and without mechanical ventilation on day 14|Patients alive and without mechanical ventilation on day 28|Patients alive and without vasopressors on day 28|Days without vasopressors for 28 days|Patients cured at 15 days|Incidence of Treatment-Emergent Adverse Events,"Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Apices Soluciones S.L.",All,"40 Years to 80 Years   (Adult, Older Adult)"
67,NCT04345679,Anti COVID-19 Convalescent Plasma Therapy,,Recruiting,No Results Available,COVID 19,Biological: anti-SARS-CoV-2 convalescent plasma,Changing of viral load of SARS-CoV2|Changes in immunglobulin G COVID-19 antibody titer|Changes at the cytokine pattern|Intensive Care Unit Admission|Length of hospital stay|Duration of mechanical ventilation|Clinical Status|Mortality,Orthosera Kft.|Semmelweis University|University of Pecs|Hungarian National Blood Service|Humán Bioplazma Kft - Kedrion,All,"18 Years and older   (Adult, Older Adult)"
68,NCT04668404,Study of Coagulation Profile and Role of Heparin Like Effect in Patients With COVID-19,COVID-19,Recruiting,No Results Available,Covid19|Hypercoagulable States Nec,Diagnostic Test: Sonoclot,"Correlation of of conventional coagulation tests with point of care coagulation test using sonoclot in COVID-19 patients.|Clinical Evidence of thrombosis|Coagulation-related Bleeding Event|Presence of Endogenous Heparinoids as demonstrated on POC test [ Time Frame 0, 3 days]|Intensive care admission duration|28 day mortality",Postgraduate Institute of Medical Education and Research,All,"18 Years to 80 Years   (Adult, Older Adult)"
69,NCT04355715,Combination of Chest Scanography and Nasal Viral Detection Test to Detect COVID-19 Positive Patients Before Surgical Intervention in a University Hospital During Coronavirus Pandemia,COVID-Scan,Completed,No Results Available,COVID 19|SARS-Cov-2,,Confirmed diagnosis of COVID-19 infection|Incidence of unexpected COVID-19 positive patients admitted to the hospital|Number of contaminating events avoided by the early detection of COVID-19 patients|Incidence of SARS-Cov-2 seroconversion,"University Hospital, Montpellier",All,"18 Years to 99 Years   (Adult, Older Adult)"
70,NCT04339322,Characteristics and Outcome of Coronavirus Disease 2019 (COVID-19) in Egypt,COVID-19,Not yet recruiting,No Results Available,"Characteristics Diseases|Outcome, Fatal",Other: Follow up,Demographics of Coronavirus Disease 2019 (COVID-19) in the cohort group|Clinical manifestations of Coronavirus Disease 2019 (COVID-19)|Laboratory data of included Coronavirus Disease 2019 (COVID-19) cohort|Radiological features of Coronavirus Disease 2019 (COVID-19) cohort|outcomes of Coronavirus Disease 2019 (COVID-19) infection in the cohort group,Assiut University,All,"Child, Adult, Older Adult"
71,NCT04674644,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,,Completed,Has Results,COVID-19 Pandemic,Behavioral: The psychosocial effects of COVID-19 pandemic on dental professionals,The Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 Scale|The Psychosocial Effects of COVID-19 Pandemic Using the Turkish Version of the Coronavirus Anxiety Scale,Suleyman Demirel University,All,"23 Years and older   (Adult, Older Adult)"
72,NCT04453748,"The Assessment of the Prevalence, Clinical Course and Treatment of COVID-19 Complications",,Enrolling by invitation,No Results Available,COVID-19|Coronavirus Infection|Sars-CoV2|Complications,Other: Complex diagnostic panel,Prevalence of COVID-19 complications|Assessment of risk factors of COVID-19 complications,Silesian Centre for Heart Diseases|Medical Research Agency - Agencja Badań Medycznych|Medical University of Silesia,All,"18 Years to 120 Years   (Adult, Older Adult)"
73,NCT04811391,COVID-19 Vaccine Effectiveness in Albanian Health Workers,COVEAL,Recruiting,No Results Available,Covid19,Biological: COVID-19 vaccine,COVID-19 vaccine effectiveness|COVID-19 PCR confirmation|Vaccine effectiveness by age|Vaccine effectiveness by co-morbidities,"Institute of Public Health, Albania|World Health Organization|Centers for Disease Control and Prevention|Southeast Europe Center for Infectious Diseases Surveillance and Control|EPICONCEPT",All,"16 Years and older   (Child, Adult, Older Adult)"
74,NCT04381871,Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients,GA&COVID19,Not yet recruiting,No Results Available,COVID 19,Dietary Supplement: Acacia Senegal|Dietary Supplement: Pectin,Mean change from baseline score of Immune Response to end of the trial ( Time Frame: up to 4 weeks )|Mortality rate|Determine viral load in each patient,Al-Neelain University|University of Khartoum,All,"5 Years to 90 Years   (Child, Adult, Older Adult)"
75,NCT04323787,Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry,COVID-19,Recruiting,No Results Available,Coronavirus,Other: observational,ICU and hospital mortality of COVID-19 patients|30 days mortality,Mayo Clinic|Society of Critical Care Medicine|Boston University,All,"Child, Adult, Older Adult"
76,NCT04510207,"A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above",COVID-19,Recruiting,No Results Available,COVID-19,Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell)|Biological: Placebo,The incidence of COVID-19 cases after two-doses of vaccination|The incidence of severe cases of SARS-CoV-2 pneumonia and deaths accompanied by COVID-19 after two-doses of vaccination|The incidence of any adverse reactions/events|The incidence of serious adverse events (SAE)|The Geometric Mean Titer (GMT) of anti-SARS-CoV-2 neutralizing antibody|The four-fold increase rate of anti-SARS-CoV-2 neutralizing antibody|The Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody|The 4-fold increase rate of anti-SARS-CoV-2 neutralizing antibody,"China National Biotec Group Company Limited|G42 Healthcare company|Abu Dhabi Health Services Company|Wuhan Institute of Biological Products Co., Ltd|Beijing Institute of Biological Products Co Ltd.",All,"18 Years and older   (Adult, Older Adult)"
77,NCT04760990,A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.,MS COVID-19,Recruiting,No Results Available,Multiple Sclerosis|COVID-19 (Severe Coronavirus Disease 2019),Other: data collection|Other: analysis of blood samples,Incidence of severe COVID-19 as defined by the WHO clinical progression scale (Score 6-9)|COVID-19 related death defined by the WHO clinical progression scale (Score 10)|Proportion of patients with Anti-SARS-CoV-2 seroconversion|Change in mean titers of IgM- and IgG-antibodies against SARS-CoV-2|Change in individual titers of IgM- and IgG-antibodies against SARS-CoV-2|Proportion of total confirmed SARS-CoV-2-infections (independent of WHO clinical progression scale Score).,"University Hospital, Basel, Switzerland|Swiss Multiple Sclerosis Society",All,"18 Years and older   (Adult, Older Adult)"
78,NCT04387929,Detection of Anti-COVID-19 Antibody Levels in an Hospital Population,,Recruiting,No Results Available,COVID-19,Diagnostic Test: Detection of anti-COVID-19 antibody level,SARS-CoV-2 levels of IgG antibodies|SARS-CoV-2 viral load in nasopharyngeal swab of IgG positive subjects|Epidemiology correlations,Istituto Clinico Humanitas,All,"18 Years to 90 Years   (Adult, Older Adult)"
79,NCT04330261,Clinical Characteristics and Outcomes of Pediatric COVID-19,PERN-COVID-19,Recruiting,No Results Available,"COVID-19|SARS-CoV-2 Infection|Pediatric ALL|Pneumonia, Viral|Pandemic Response",Other: Exposure (not intervention) - SARS-CoV-2 infection,Clinical characteristics of children with SARS-CoV-2|Factors associated with severe COVID-19 outcomes|Health care resource utilization for COVID-19 patient management|Sensitivity and specificity of COVID-19 case screening policies,University of Calgary,All,"up to 18 Years   (Child, Adult)"
80,NCT04529460,Healthy Volunteer COVID-19 Antibody Testing Study,,Not yet recruiting,No Results Available,Covid19,Diagnostic Test: COVID-19 antibody point of care test kit,Sensitivity and specificity of the COVID-19 antibody testing kit,Royal Free Hospital NHS Foundation Trust,All,"18 Years and older   (Adult, Older Adult)"
81,NCT04392323,Incidence of COVID-19 Test Conversion in Post-surgical Patients,,Recruiting,No Results Available,Sars-CoV2,Diagnostic Test: COVID-19 PCR and Serology,COVID-19 Test Conversion|Duration of Hospitalization|Rate of self-reported COVID-19 exposure|Rate of complications from COVID-19,Northwell Health,All,"18 Years and older   (Adult, Older Adult)"
82,NCT04565522,Transmission of COVID-19 Virus Among Patients and Staff in Dialysis Centers,DIAL-COVID-19,Not yet recruiting,No Results Available,Covid19|Dialysis|Nurse-Patient Relations,Other: Prospective observation,"incident risk of COVID-19 infection|Evaluate the morbidity of COVID-19|Evaluate the mortality of COVID-19|Estimate the predictive role of comorbidities, inflammation indexes and therapy on the hospitalisation rate|Estimate the predictive role of comorbidities, inflammation indexes and therapy on the mortality rate|Evaluate the infective role of dialysis staff towards patients|Evaluate the infective role of patients towards dialysis staff","Simeone Andrulli, MD|A. Manzoni Hospital",All,"18 Years and older   (Adult, Older Adult)"
83,NCT04799392,NOWDx Test for the Detection of Antibodies to COVID-19 in Lay Persons,,Recruiting,No Results Available,COVID-19|SARS-CoV-2|Coronavirus,Device: NOWDx COVID-19 Test,Percentage of clinical agreement between NOWDx COVID-19 Test and emergency use authorized or FDA cleared comparator|Positivity rate of NOWDx COVID-19 Tests in vaccinated persons,"NOWDiagnostics, Inc.",All,"2 Years and older   (Child, Adult, Older Adult)"
84,NCT04816318,Policy Responses Against the COVID-19 Pandemic in Latin America,,Not yet recruiting,No Results Available,Covid19|Infectious Disease|Death|SARS-CoV Infection,Other: Social and public health measures against COVID-19|Other: Control,7-day moving average of daily confirmed cases of COVID-19/SARS-CoV-2|Time-varying reproductive number of confirmed cases of COVID-19/SARS-CoV-2|7-day moving average of daily confirmed deaths of COVID-19/SARS-CoV-2,University of Chile,All,"Child, Adult, Older Adult"
85,NCT04690413,NOWDx Test for the Detection of Antibodies to COVID-19,,Completed,No Results Available,COVID-19|SARS-CoV-2|Coronavirus,Device: NOWDx COVID-19 Test,Percentage of clinical agreement between NOWDx COVID-19 Test and emergency use authorized or FDA cleared comparator.,"NOWDiagnostics, Inc.",All,"18 Years and older   (Adult, Older Adult)"
86,NCT04349202,Beaumont Health Large-scale Automated Serologic Testing for COVID-19,BLAST COVID-19,Recruiting,No Results Available,COVID-19|Coronavirus Infection|Severe Acute Respiratory Syndrome Coronavirus 2,Diagnostic Test: EUROIMMUN assay,Prevalence COVID antibodies in employees of Beaumont Health|COVID-19 re-infection in participants positive for antibodies to SARS-CoV-2|Correlation of dried blood spot and standard blood sampling positive for COVID-19 IgG antibodies|Correlation of dried blood spot and standard blood sampling negative for COVID-19 IgG antibodies|Correlation of dried blood spot and standard blood sampling positive for COVID-19 IgA antibodies|Correlation of dried blood spot and standard blood sampling negative for COVID-19 IgA antibodies|Reproducibility of SARS-CoV-2 IgG antibody detection from dried blood spots|Stability of dried blood spots for SARS-CoV-2 IgG antibody detection|Effect of shipping on dried blood spot samples for SARS-CoV-2 IgG antibody detection|Accuracy of participant-performed blood spot collection for SARS-CoV-2 IgG antibody detection|Ease of participant-performed blood spot collection|Correlation of SARS-CoV-2 antibodies between immediate family members,William Beaumont Hospitals,All,"18 Years and older   (Adult, Older Adult)"
87,NCT04474496,Impact of COVID-19 on Marshallese Communities in the U.S.,,Completed,Has Results,COVID-19,Other: Assessing the impact of COVID-19,Personal Preventative Behaviors to Decrease Risk of COVID-19 Exposure|Workplace Preventative Actions to Decrease Risk of COVID-19 Exposure|Effects of COVID-19 on General Health Status|Effects of COVID-19 on Access to Healthcare Services|Effects of COVID-19 on Dietary Habits|Effects of COVID-19 on Physical Activity Behaviors (Not Specifically for Exercise)|Effects of COVID-19 on Physical Activity Behaviors (Specifically for Exercise)|Effects of COVID-19 on Weight|Effects of COVID-19 on HbA1c (Glycated Hemoglobin)|Barriers to Type 2 Diabetes Management Due to COVID-19|COVID-19 Screening|COVID-19 Testing|COVID-19 Vaccine Willingness/Hesitancy|Trusted Sources of COVID-19 Information|Effects of COVID-19 on Housing|Effects of COVID-19 on Employment|Effects of COVID-19 on Income|Sources of Stress During COVID-19,University of Arkansas|Patient-Centered Outcomes Research Institute,All,"18 Years and older   (Adult, Older Adult)"
88,NCT04466657,Antioxidant Therapy for COVID-19 Study,GSHSOD-COVID,Not yet recruiting,No Results Available,Covid-19,Dietary Supplement: Antioxidation Therapy|Other: Standard of Care,Time to clinical improvement|Time to SARS-CoV-2 negativity|Clinical status on day 14|Proportion of participants with SARS-CoV-2 PCR negative result at Day 7|Proportion of participants with SARS-CoV-2 PCR negative result at Day 28|28 Day mortality|Duration of hospitalization in survivors|Time from treatment initiation to death,Obafemi Awolowo University|Borno State Ministry of Health|Ogun State Ministry of Health|Abia State Ministry of Health|Sokoto State Ministry of Health|Benue State Minsitry of Health|University of Calabar Teaching Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)"
86,NCT04349202,Beaumont Health Large-scale Automated Serologic Testing for COVID-19,BLAST COVID-19,Recruiting,No Results Available,COVID-19|Coronavirus Infection|Severe Acute Respiratory Syndrome Coronavirus 2,Diagnostic Test: EUROIMMUN assay,Prevalence COVID antibodies in employees of Beaumont Health|COVID-19 re-infection in participants positive for antibodies to SARS-CoV-2|Correlation of dried blood spot and standard blood sampling positive for COVID-19 IgG antibodies|Correlation of dried blood spot and standard blood sampling negative for COVID-19 IgG antibodies|Correlation of dried blood spot and standard blood sampling positive for COVID-19 IgA antibodies|Correlation of dried blood spot and standard blood sampling negative for COVID-19 IgA antibodies|Reproducibility of SARS-CoV-2 IgG antibody detection from dried blood spots|Stability of dried blood spots for SARS-CoV-2 IgG antibody detection|Effect of shipping on dried blood spot samples for SARS-CoV-2 IgG antibody detection|Accuracy of participant-performed blood spot collection for SARS-CoV-2 IgG antibody detection|Ease of participant-performed blood spot collection|Correlation of SARS-CoV-2 antibodies between immediate family members,William Beaumont Hospitals,All,"18 Years and older   (Adult, Older Adult)"
87,NCT04474496,Impact of COVID-19 on Marshallese Communities in the U.S.,,Completed,Has Results,COVID-19,Other: Assessing the impact of COVID-19,Personal Preventative Behaviors to Decrease Risk of COVID-19 Exposure|Workplace Preventative Actions to Decrease Risk of COVID-19 Exposure|Effects of COVID-19 on General Health Status|Effects of COVID-19 on Access to Healthcare Services|Effects of COVID-19 on Dietary Habits|Effects of COVID-19 on Physical Activity Behaviors (Not Specifically for Exercise)|Effects of COVID-19 on Physical Activity Behaviors (Specifically for Exercise)|Effects of COVID-19 on Weight|Effects of COVID-19 on HbA1c (Glycated Hemoglobin)|Barriers to Type 2 Diabetes Management Due to COVID-19|COVID-19 Screening|COVID-19 Testing|COVID-19 Vaccine Willingness/Hesitancy|Trusted Sources of COVID-19 Information|Effects of COVID-19 on Housing|Effects of COVID-19 on Employment|Effects of COVID-19 on Income|Sources of Stress During COVID-19,University of Arkansas|Patient-Centered Outcomes Research Institute,All,"18 Years and older   (Adult, Older Adult)"
88,NCT04466657,Antioxidant Therapy for COVID-19 Study,GSHSOD-COVID,Not yet recruiting,No Results Available,Covid-19,Dietary Supplement: Antioxidation Therapy|Other: Standard of Care,Time to clinical improvement|Time to SARS-CoV-2 negativity|Clinical status on day 14|Proportion of participants with SARS-CoV-2 PCR negative result at Day 7|Proportion of participants with SARS-CoV-2 PCR negative result at Day 28|28 Day mortality|Duration of hospitalization in survivors|Time from treatment initiation to death,Obafemi Awolowo University|Borno State Ministry of Health|Ogun State Ministry of Health|Abia State Ministry of Health|Sokoto State Ministry of Health|Benue State Minsitry of Health|University of Calabar Teaching Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)"
89,NCT04427358,RT-PCR SARS-CoV-2 at 1 Month of COVID-19 Infection in the Geriatric Population,COVID-19GAOM,Completed,No Results Available,Covid-19,,"1. Analysis of the rate of RT-PCR SARS-CoV-2 positive at 1 month of COVID infection|2. Assess quantitative evaluation of a nasopharyngeal swab SARS-CoV-2 RT-PCR test|Assessment of late stool SARS-CoV-2 RT-PCR, serological status and associated factors with death and RT-PCR results 1 month after the date of first symptom onset","University Hospital, Strasbourg, France",All,70 Years and older   (Older Adult)
90,NCT04811664,A Study of SARS CoV-2 Infection and Potential Transmission in University Students Immunized With Moderna COVID-19 Vaccine,CoVPN 3006,Recruiting,No Results Available,SARS-CoV-2 Infection,Biological: Moderna COVID-19 Vaccine,"Efficacy of Moderna COVID-19 Vaccine against SARS-CoV-2 infection|Effect of Moderna COVID-19 Vaccine on peak nasal viral load|Impact of Moderna COVID-19 Vaccine on secondary transmission of SARS-CoV-2 infection|Efficacy of Moderna COVID-19 Vaccine to prevent serologically confirmed SARS-CoV-2 infection|Efficacy of Moderna COVID-19 Vaccine against COVID-19 disease confirmed by PCR test and symptoms|Effect of Moderna COVID-19 Vaccine on magnitude of viral load over time|Efficacy of Moderna vaccine regardless of baseline serostatus (SARS-CoV-2 infection by PCR)|Effect of Moderna vaccine on viral load regardless of baseline serostatus (Viral load)|Effect of Moderna vaccine on secondary status regardless of baseline serostatus (Secondary transmission events)|Immunogenicity of Moderna COVID-19 vaccine|Immune responses as correlates of risk of SARS-CoV-2 acquisition, viral load, secondary infection, and COVID-19 disease|Efficacy of Moderna COVID-19 vaccine against asymptomatic SARS-CoV-2 infection|Efficacy of Moderna COVID-19 Vaccine against SARS-CoV-2 infection and COVID-19 disease|Effect of Moderna COVID-19 Vaccine on viral load|Effect of Moderna COVID-19 Vaccine on secondary transmission",National Institute of Allergy and Infectious Diseases (NIAID),All,18 Years to 26 Years   (Adult)
91,NCT04664023,"Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution",BIOMARK-COVID,Recruiting,No Results Available,Covid19,"Procedure: Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection",Neutralizing antibodies|T CD8 lymphocytes|Inflammatory markers|Metabolic markers,Poitiers University Hospital,All,"18 Years and older   (Adult, Older Adult)"
91,NCT04664023,"Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution",BIOMARK-COVID,Recruiting,No Results Available,Covid19,"Procedure: Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection",Neutralizing antibodies|T CD8 lymphocytes|Inflammatory markers|Metabolic markers,Poitiers University Hospital,All,"18 Years and older   (Adult, Older Adult)"
92,NCT04404062,Validation of COVID-19 Tests,,"Active, not recruiting",No Results Available,COVID-19,Diagnostic Test: Covid-19 Rapid Test Kit (RAPG-COV-019)|Diagnostic Test: Quantitative IgG Test,Identification of asymptomatic carriers of SARS-CoV-2|Validation of the ability of the immunoassay kit to detect antibodies to SARS-CoV-2|Development of a quantitative laboratory reference test for the measurement of SARS-CoV-2|Exploration of SARS-CoV-2 epidemiology,Richmond Pharmacology Limited,All,"18 Years to 70 Years   (Adult, Older Adult)"
93,NCT04376996,Slovenian National COVID-19 Prevalence Study,SLO-COVID-19,Recruiting,No Results Available,COVID-19|SARS-CoV-2,Diagnostic Test: NO intervention planned due to the observational study design - only a diagnostic testing,Prevalence of SARS-CoV-2 RNA in nasopharyngeal samples|Prevalence of anti-SARS-CoV-2 antibodies in blood samples,University of Ljubljana,All,"Child, Adult, Older Adult"
94,NCT04370288,Clinical Application of Methylene Blue for Treatment of Covid-19 Patients,Covid-19,Recruiting,No Results Available,Covid-19,"Drug: MCN (Methylene blue, vitamin C, N-acetyl cysteine)",Proportion of patients remaining free of need for mechanical ventilation in both groups|Mortality rate in both groups|Improvement in Pa02/Fi02 ratio in both groups|Duration of hospital stay in both group.|Duration of Intensive Care Unit stay in both groups|Days free of dialysis in both groups|C-reactive proteins|WBC Count,Mashhad University of Medical Sciences,All,"18 Years to 90 Years   (Adult, Older Adult)"
95,NCT04706403,Views on COVID-19 and Vaccination,,"Active, not recruiting",No Results Available,Covid19,Behavioral: Healthcare Providers' Communication about the COVID-19 Vaccine,Intent to be vaccinated against COVID-19.|Predictors of intent to be vaccinated against COVID-19.,"University of Massachusetts, Worcester",All,"18 Years and older   (Adult, Older Adult)"
96,NCT04393402,Lung Ultrasound Score in Covid 19 Infectious Disease in Critical Care (LUS-COVID19),LUS-COVID19,Recruiting,No Results Available,COVID,Procedure: lung ultrasound (LUS),LUS applicability with COVID 19|Radiographic correlation (chest Xray and tomodensitometry)|LUS Mortality prediction|Prediction of Prone position response,Centre Hospitalier Universitaire de Nice,All,"18 Years to 95 Years   (Adult, Older Adult)"
97,NCT04548908,Prevalence Of COVID-19 Among Health-workers in a French General Hospital,POCAH-COVID,Recruiting,No Results Available,Covid19,"Diagnostic Test: Serelogy testing, RT PCR",General prevalence of COVID-19|Number of asymptomatic healthcare workers|Number of symptomatic healthcare workers|Number of healthcare workers with a severe form of COVID-19 which led to an hospitalization|Number of healthcare workers infected with COVID-19 and hospitalized in a critical care unit|Influencing factors of the prevalence of the COVID-19 among healthcare workers,Centre Hospitalier Sud Essonne,All,"18 Years and older   (Adult, Older Adult)"
98,NCT04582331,Improving Real-time COVID-19 Monitoring Through Smartphone Voice Analysis,,Recruiting,No Results Available,Covid19,Other: Smartphone-based voice and self-reported symptom collection,Vocal biomarker performance in COVID-19 positive vs. healthy controls|Vocal biomarker vs. symptom burden correlation in COVID-19 positive|Vocal biomarker performance in COVID-19 positive vs. COVID-19 negative symptomatic,Sonde Health,All,"12 Years and older   (Child, Adult, Older Adult)"
100,NCT04379284,Risks of COVID19 in the Pregnant Population,,Recruiting,No Results Available,COVID19,Other: Biospecimen collection,Determine the prevalence of maternal fetal transmission of COVID19|Describe the outcomes of COVID19 positive pregnancies|Understand the placental impact of COVID19 in pregnancy at various gestational ages,Mayo Clinic,Female,18 Years to 45 Years   (Adult)
99,NCT04352764,ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings,,Recruiting,No Results Available,Covid19,Diagnostic Test: CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test,prevalence of COVID-19 exposure|correlation between the test results with the presence or lack of COVID-19 symptoms or illness|correlate pre-existing risk factors with test results and baseline symptoms|correlate subsequent healthcare utilization with test results and baseline symptoms,Texas Cardiac Arrhythmia Research Foundation,All,"Child, Adult, Older Adult"